Moleculin Begins Clinical Testing Site Development Efforts in Poland

Moleculin Biotech (NASDAQ:MBRX) announced it has selected Bioscience SA to begin identifying and preparing clinical testing sites in Poland for Annamycin, their drug candidate treatment against relapsed or refractory acute myeloid leukemia.
As quoted in the press release:

The Company announced on June 15^th an expansion of its agreement with Theradex Systems, Inc. to include oversite of clinical trial activity in Poland and the appointment of a Lead European Principal Investigator on July 6, 2017.
“Engaging Bioscience gives us experienced boots on the ground in Poland,” commented Walter Klemp, CEO of Moleculin, “which we believe is critical, not only for ensuring tight coordination between the US and Polish sites in our upcoming Annamycin clinical trial (which would commence only if our IND for Annamycin is permitted), but also to ensure we have the full benefit of local knowledge regarding site performance and regulatory compliance.”
Mr. Klemp continued: “one of the biggest challenges for most clinical trials is recruiting the right patients on a timely basis. We believe adding Polish sites to our planned trial introduces a significant population of qualified patients, and selecting Bioscience helps ensure we reach those patients effectively and efficiently.”

Click here to read the full press release.

Source: www.marketwired.com